Antifibrillatory efficacy of ersentilide, a novel β-adrenergic and I(kr) blocker, in conscious dogs with a healed myocardial infarction

Cardiovascular Research

Volumn 40, Issue 1, 1998, Pages 56-63

  Adamson, Philip B ^a,b,c   Vanoli, Emilio ^b,c,d,e   Hull, Stephen S ^b   Foreman, Robert D ^b   Schwartz, Peter J ^b,d,e  

^a BSEB 306   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF PAVIA   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Antiarrhythmic agents; Autonomic nervous system; K channel; Myocardial infarction; Sudden death

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ERSENTILIDE; POTASSIUM CHANNEL; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HEART INFARCTION; HEART MUSCLE POTENTIAL; HEART RATE; HEART VENTRICLE FIBRILLATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL;

ACTION POTENTIALS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CARDIAC PACING, ARTIFICIAL; DOGS; ELECTRIC STIMULATION; EXERTION; HEART RATE; IMIDAZOLES; MYOCARDIAL INFARCTION; POTASSIUM CHANNEL BLOCKERS; PROPANOLAMINES; STELLATE GANGLION; VENTRICULAR FIBRILLATION;

EID: 0032189613     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00137-0     Document Type: Article

References (28)

1. [1] The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New Engl J Med 1989;321:406-412.
2. [2] Waldo AL, Camm AJ, deRuyter H, et al. For the SWORD Investigators: Effect of D-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12.
3. [3] Julian DG, Camm AJ, Frangin G, et al. On behalf of the EMIAT investigators: The European Myocardial Infarct Amiodarone Trial (EMIAT): The effect of amiodarone on mortality in patients with left ventricular dysfunction surviving a recent myocardial infarction. Lancet 1997;349:667-674.
4. [4] Cairns JA, Connolly SJ, Roberts R, Gent M. For the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial investigators: Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997;349:675-682.
5. [5] Julian DG, Prescott RJ, Jackson FS, Szekely P. A controlled trial of sotalol for 1 year after myocardial infarction. Lancet 1982;1:1142-1147.
6. [6] Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. New Engl J Med 1993;329:452-458.
7. [7] Ward DE, Camm AJ. Dangerous ventricular arrhythmias - can we predict drug efficacy?. New Engl J Med 1993;329:498-499.
8. [8] Hohnloser SH, Woosley RL. Sotalol. New Engl J Med 1994;331:31-38.
9. [9] The DIAMOND Study Group, Denmark Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patient characteristics of the DIAMOND studies. Danish Investigations of Arrhythmia and Mortality On Dofetilide. Clin Cardiol 1997;20(8):704-710.
10. [10] Task Force of the Working Group on Arrhythmias of the European Society of CardiologyBigger Jr. JT, Breithardt G, Brown AM, et al. The Sicilian Gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991;84:1831-1851.
11. [11] Task Force of the Working Group on Arrhythmias of the European Society of CardiologyBigger Jr. JT, Breithardt G, Brown AM, et al. The Sicilian Gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Eur Heart J 1991;12:1112-1131.
12. [12] Lynch JJ, Coskey LA, Montgomery DG, Lucchesi BR. Prevention of ventricular fibrillation by dextrorotatory sotalol in a conscious canine model of sudden coronary death. Am Heart J 1985;109:949-958.
13. + channel blockade in the prevention of ventricular fibrillation in dogs with acute ischemia and enhanced sympathetic activity. J Cardiovascular Pharmacol 1995;26:847-854.
14. Ks blockade in the prevention of ischemic ventricular fibrillation after myocardial infarction. Eur Heart J 1997;18 (Abstr Suppl):263.
15. [15] Sanguinetti MC, Jurkiewicz NK, Scott A, Siegl PKS. Isoproterenol antagonizes prolongation of refractory period by the class III antiarrhythmic agent E-4031 in guinea pig myocytes: Mechanism of action. Circ Res 1991;68:77-84.
16. [16] Corr PB, Yamada KA, Witkowski FX. Mechanisms controlling cardiac autonomic function and their relation to arrhythmogenesis. In: Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE, editors. The heart and the cardiovascular system. New York: Raven Press, 1986:1343-1403.
17. [17] Schwartz PJ, Priori SG. Sympathetic nervous system and cardiac arrhythmias. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology: from cell to bedside. Philadelphia: WB Saunders, 1990:330-343.
18. [18] Argentieri TM, Troy HH, Carroll MS, Doroshuk SM, Sullivan ME. Electrophysiologic activity and antiarrhythmic efficacy of CK-3579, a new class III antiarrhythmic agent with β-adrenergic blocking properties. J Cardiovasc Pharmacol 1993;21:647-655.
19. [19] Lee JH, Rosenshtraukh L, Beloshapko G, Rosen MR. The electrophysiologic effects of ersentilide on canine hearts. Eur J Pharmacol 1995;285:25-35.
20. [20] Schwartz PJ, Billman GE, Stone HL. Autonomic mechanisms in ventricular fibrillation induced by myocardial ischemia during exercise in dogs with a healed myocardial infarction: an experimental preparation for sudden cardiac death. Circulation 1984;69:780-790.
21. [21] Schwartz PJ, Vanoli E, Stramba-Badiale M, De Ferrari GM, Billman GE, Foreman RD. Autonomic mechanisms and sudden death. New insights from analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction. Circulation 1988;78:969-979.
22. [22] Schwartz PJ, Vanoli E. Animal models for the study of sudden cardiac death and their applicability to clinical cardiology. In: Allessie MA, Fromer M, editors. Atrial and ventricular fibrillation: mechanisms and device therapy. Armonk, NY: Futura, 1997:15-35.
23. + channel blockers. J Am Coll Cardiol 1995;25:1609-1614.
24. [24] Patterson E, Lynch JJ, Lucchesi BR. Antiarrhythmic and antifibrillatory actions of the β-adrenergic receptor antagonist, D,L-sotalol. J Pharmacol Exp Ther 1984;230:519-526.
25. [25] La Rovere MT, Bigger Jr. JT, Marcus FI, Mortara A, Schwartz PJ. For the ATRAMI Investigators: Baroreflex sensitivity and heart rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 1998;351:478-484.
26. [26] Chi L, Mu D, Driscoll EM, Lucchesi BR. Antiarrhythmic and electrophysiologic actions of CK-3579 and semantilide in a conscious canine model of sudden coronary death. J Cardiovasc Pharmacol 1990;16:312-324.
27. [27] Black SC, Chi L, Mu D, Lucchesi BR. The antifibrillatory actions of UK-68,798, a class III antiarrhythmic agent. J Pharmacol Exp Ther 1991;258:416-423.
28. [28] Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev 1989;69:1049-1149.